Leptospirosis

Verify with FDA CVM →

79 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
79
Total Reports
7
Deaths Reported
890.0%
Death Rate

Active Ingredients

Leptospirosis

Administration Routes

SubcutaneousUnknown

Species Affected

Dog 79

Most Affected Breeds

Retriever - Labrador 7
Crossbred Canine/dog 6
Boxer (German Boxer) 5
Terrier - Yorkshire 3
Shepherd Dog - Australian 3
Terrier - Jack Russell 3
Chihuahua 3
Shepherd Dog - German 2
Terrier (unspecified) 2
Shih Tzu 2

Most Reported Reactions

Vomiting 36
Lethargy (see also Central nervous system depression in 'Neurological') 14
Diarrhoea 14
Facial swelling (see also 'Skin') 9
Hives (see also 'Skin') 8
Anaphylaxis 8
Panting 7
Lethargy (see also Central nervous system depression in Neurological) 7
Anorexia 6
Elevated alanine aminotransferase (ALT) 6
Seizure NOS 5
Lack of efficacy - NOS 5

Outcome Breakdown

Ongoing
33 (41.8%)
Recovered/Normal
29 (36.7%)
Outcome Unknown
10 (12.7%)
Euthanized
4 (5.1%)
Died
3 (3.8%)

Data Summary

Metric Value
Total adverse event reports 79
Reports involving death 7
Case-fatality rate (reported events) 890.0%
Distinct species in reports 1
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Leptospirosis Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 79 adverse event reports referencing Leptospirosis, including 7 reports in which the animal died — a 890.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Leptospirosis. Reported administration routes include Subcutaneous, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Leptospirosis reports are Dog (79 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (7), Crossbred Canine/dog (6), Boxer (German Boxer) (5) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Leptospirosis are Vomiting (36), Lethargy (see also Central nervous system depression in 'Neurological') (14), Diarrhoea (14), Facial swelling (see also 'Skin') (9). Of the 79 reports with a coded outcome, Ongoing is the leading category at 41.8%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Leptospirosis.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial